Daré Bioscience to Host Third Quarter 2020 Financial Results and Company Update Conference Call and Webcast on November 12, 2020
Daré Bioscience (NASDAQ: DARE) will host a conference call on November 12, 2020, at 4:30 p.m. ET to discuss its financial results for Q3 2020. The event will provide insights into the company's portfolio focused on women's health, including innovative products like Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1. Investors can join via phone or webcast, with a replay available until November 19, 2020. The company's mission is to enhance treatment options in areas including contraception and male sexual health.
- Upcoming conference call for Q3 2020 results could boost investor confidence.
- Focus on innovative women's health products may attract interest.
- None.
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 12, 2020, to review its financial results for the quarter ended September 30, 2020 and to provide a Company update.
To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 6519434. The live webcast can be accessed under “Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 6519434. The call and webcast replay will be available until November 19, 2020.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream,
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.
Contact:
Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
212.213.0006
Source: Daré Bioscience
FAQ
When is Daré Bioscience's Q3 2020 financial results conference call?
How can I access the Daré Bioscience conference call?
What products does Daré Bioscience focus on?
What are the key products in Daré Bioscience's portfolio?
When will the replay of the conference call be available?
